Skip to main content
Premium Trial:

Request an Annual Quote

Startup RainDance Raises $23.7M to Develop Lab-on-Chip for Cell Sorting, HCS, and More

BOSTON – RainDance Technologies, a lab-on-a-chip startup founded in 2004, has raised $23.7 million in first-round venture financing to help develop a benchtop laboratory system that it claims will dramatically reduce the costs of cell sorting, high-content screening, and other laboratory applications.
The founder of the company, Jonathan Rothberg, has a successful track record commercializing biotech startups. In 1991, he founded Curagen, a genomics-based drug discovery firm. In 2000, he followed that up with the creation of 454 Life Sciences, a Curagen subsidiary dedicated to developing next-generation sequencing technology that is in the process of being acquired by Roche.
Now, he has set his sights on moving a full suite of laboratory instruments to the scale of a microchip.
In a keynote Tuesday at Cambridge Healthtech Institute’s Bio-IT World conference, Rothberg said that the RainDance platform, called the Personal Laboratory System, is a “generalization” of a technology originally developed for the 454 sequencing platform: micron-sized droplets that capture and amplify DNA.
Rothberg said that the RainDance platform takes the droplet idea and moves it to a “universal” microfluidic chip.
According to Rothberg, the droplets are self-contained compartments that encapsulate biological samples using surfactant chemistry. They float in a biocompatible oil that separates them while ensuring that the cells they contain remain alive. The droplets move through microfluidic channels that are preconfigured to enable a range of common laboratory tasks, such as formulate, load, combine, split, mix, store, detect, and so on. These individual modules are assembled into so-called NanoReactors to perform specific experiments, including fluorescence detection, cell sorting, sample prep for DNA sequencing, drug screening, chemical synthesis, and more, Rothberg said.
One application, he noted, is “the world’s smallest cell sorter,” which can sort based on secreted molecules, “not just what’s on the surface of the cell.” He said that the technology can detect fluorescence at rates up to 10,000 per second, which makes it applicable for high-content screening.
RainDance’s goal is to enable the same kinds of advances for laboratory research that the personal computer and the Internet did for information technology, Rothberg said, describing the droplets as “packets of chemicals” that are analogous to the “packets” of information that are transferred today over the web.
Rothberg acknowledged that lab-on-a-chip technologies have been in development for around 30 years and have yet to see commercial success. But he noted that most microfluidics systems to date have taken a different approach that relies on micromechanical valves to separate fluids rather than discrete droplets. This approach, he said, is more difficult to fabricate because of the complex valve mechanisms, and also raises the risk of contamination when different samples are run through the same channel.
The NanoReactors are manufactured using injection molding, which could eventually yield costs as little as $1 per chip, he said. RainDance is currently hand-molding its prototype chips at a cost of $20 to $100 per chip.
The main advantage of the Personal Laboratory System over previous lab-on-a-chip systems, Rothberg said, is the droplet-based approach, which ensures that sample materials never touch the walls of the microfluidic channels, eliminating the risk of contamination. This capability makes the technology a good candidate for diagnostic applications, he said.
Rothberg said that RainDance has received a milestone payment from Novozymes for a proof-of-concept project to use the PLS platform to improve enzymes for laundry detergent. In the project, he said, PLS was able to characterize bacterial strains at a rate of 1,000 per second.    
The company is also collaborating with Bayer to port several high-throughput screening assays to the PLS platform, he said.
The company expects to begin delivering systems to early-access customers later this year and to fully commercialize the platform in 2008.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.